Kyverna became the first company this month to initiate a BLA for CAR-T to treat an autoimmune condition. CEO Warner Biddle describes Stiff Person Syndrome and what it means as PoC
He discusses the data from the registrational trial that was presented at AAN last month, and the timeline of the BLA. Plus, myasthenia gravis, which is already in a pivotal, and other conditions the company is considering.










.png)